查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609164

神经科学市场：按类型、最终用户划分 - 2025-2030 年全球预测

Neuroscience Market by Type (Diagnostic Solution, Drug Therapy, Non-drug Therapy), End-User (Diagnostic Laboratories, Hospitals, Research & Academic Institutes) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年神经科学市场规模为137.7亿美元，预计2024年将达到151.1亿美元，复合年增长率为10.34%，2030年将达274.2亿美元。

神经科学作为市场研究领域的范围涵盖生物和认知科学的研究和应用，以了解和增强人脑功能。该领域的需求源于对治疗神经系统疾病、心理健康挑战和退化性疾病的解决方案的需求不断增长。应用范围涵盖製药、生物技术、认知神经科学和神经技术，最终用途领域包括医疗、教育和国防。市场成长受到脑部影像技术进步、神经学研究资金增加以及心理健康意识增强等因素的影响。人工智慧和机器学习技术的涌入为精神卫生保健领域的个人化治疗计划和预测分析等创新提供了重大机会。此外，由于 COVID-19 大流行，远端医疗服务的扩展加速了神经科学主导的应用程式在远端医疗环境中的整合。然而，挑战依然存在，包括高昂的研发成本、监管障碍以及围绕神经技术进步的伦理考量。此外，市场细分，少数强势参与企业和大量利基开发商增加了竞争压力。创新的成熟领域包括开发非侵入性神经刺激技术、增强脑机介面技术以及探索迷幻物质的治疗潜力和神经效应。透过与大学和研究机构的合作、促进跨学科研究以及优先采用以患者为中心的产品开发方法，进一步促进业务成长。市场本质上是动态且快速发展的，要求企业对新趋势和监管变化保持警惕。因此，神经科学市场的本质是具有很高的创新潜力，但也受到收益和道德部署方面的挑战的影响，需要将研究重点和市场敏捷性进行策略性结合。

主要市场统计
基准年[2023] 137.7亿美元
预计年份 [2024] 151.1亿美元
预测年份 [2030] 274.2亿美元
复合年增长率（%） 10.34%

市场动态：揭示快速发展的神经科学市场的关键市场洞察

供需的动态交互作用正在改变神经科学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球神经系统疾病盛行率不断上升
    • 神经系统疾病药物发现和药物开发的增加
    • 越来越多地利用神经科学来增强大脑健康和认知功能
  • 市场限制因素
    • 与神经科学研究相关的高成本
  • 市场机会
    • 扩大神经科学在个人化医疗开发的应用
    • 神经科学研究的有利资助状况
  • 市场问题
    • 使用神经技术的功能限制

波特五力：驾驭神经科学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解神经科学市场的外部影响

外部宏观环境因素在塑造神经科学市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解神经科学市场的竞争格局

神经科学市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：神经科学市场供应商的绩效评估

FPNV 定位矩阵是评估神经科学市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划神经科学市场的成功之路

神经科学市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地神经系统疾病的发生率正在增加
      • 增加神经系统疾病新药的发现与开发
      • 更多地利用神经科学来增强大脑健康和认知功能
    • 抑制因素
      • 与神经科学研究相关的高成本
    • 机会
      • 神经科学在个人化医疗发展的新用途
      • 神经科学研究的有利资金筹措环境
    • 任务
      • 神经技术使用的功能限制
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章神经科学市场：依类型

  • 介绍
  • 诊断解决方案
    • 分子
      • 免疫检测
      • 装置
      • 套件和用品
      • 液相层析法
      • PCR
      • 定序
      • 软体
    • 非分子
      • 脑干听觉诱发电位
      • 脑电图测试
      • 影像
  • 药物治疗
    • 神经系统疾病
      • 阿兹海默症
      • 癫痫
      • 亨丁顿舞蹈症
      • 多发性硬化症
      • 帕金森氏症
      • 血管失智症
    • 神经精神疾病
      • 焦虑症
      • 注意力缺陷
      • 自闭症频谱
      • 失眠
      • 情绪障碍
      • 药物滥用
  • 非药物治疗
    • 行为疗法
      • 动物干预
      • 在家工作
      • 住院病人
      • 门诊病人
    • 数位医疗服务

第 7 章 神经科学市场：依最终使用者分类

  • 介绍
  • 诊断实验室
  • 医院
  • 研究/学术机构

第八章美洲神经科学市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太神经科学市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的神经科学市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Agilent Technologies, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Brain Products GmbH
  • Compumedics Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilson, Inc.
  • GL Sciences Inc.
  • Hitachi, Ltd.
  • Illumina, Inc.
  • JASCO Corporation
  • Merck KGaA
  • Metrohm AG
  • Natus Medical Incorporated
  • Novasep Holding SAS
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Restek Corporation
  • Shimadzu Corporation
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • YMC Co., Ltd.
Product Code: MRR-C002B1C9955F

The Neuroscience Market was valued at USD 13.77 billion in 2023, expected to reach USD 15.11 billion in 2024, and is projected to grow at a CAGR of 10.34%, to USD 27.42 billion by 2030.

The scope of neuroscience as a market research domain encompasses the study and application of biological and cognitive sciences to understand and enhance human brain function. This field's necessity arises from growing demand for solutions to treat neurological disorders, mental health challenges, and degenerative diseases. Applications span pharmaceuticals, biotechnology, cognitive neuroscience, and neurotechnology, with end-use sectors including healthcare, education, and defense. Market growth is influenced by factors such as technological advancements in brain imaging, increased funding for neurological research, and a heightened focus on mental health awareness. The influx of artificial intelligence and machine learning technologies presents significant opportunities for innovation, such as personalized treatment plans and predictive analytics in mental health care. Furthermore, the expansion of telehealth services amid the COVID-19 pandemic has accelerated integration of neuroscience-driven applications in remote care settings. However, challenges persist, including high R&D costs, regulatory hurdles, and ethical considerations surrounding neurotechnological advancements. Additionally, the market is fragmented, with a few dominant players and numerous niche developers, adding competitive pressure. Areas ripe for innovation include developing non-invasive neurostimulation techniques, enhancing brain-computer interface technologies, and exploring the therapeutic potential of psychedelic substances and their neural impact. Business growth can be further bolstered by leveraging collaborations with universities and research institutions, fostering interdisciplinary research, and prioritizing patient-centric approaches in product development. As the market is inherently dynamic and rapidly evolving, staying ahead requires companies to remain vigilant of emerging trends and regulatory changes. The nature of the neuroscience market is therefore characterized by high innovation potential, tempered by challenges in monetization and ethical deployment, necessitating a strategic blend of research focus and market agility.

KEY MARKET STATISTICS
Base Year [2023] USD 13.77 billion
Estimated Year [2024] USD 15.11 billion
Forecast Year [2030] USD 27.42 billion
CAGR (%) 10.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuroscience Market

The Neuroscience Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of neurological disorders worldwide
    • Rise in drug discovery and development for neurological conditions
    • Increasing use of neuroscience to enhance brain health and cognitive functions
  • Market Restraints
    • High cost associated with neuroscience research
  • Market Opportunities
    • Emerging use of neuroscience in the development of personalized medicine
    • Favorable funding landscape for neuroscience research
  • Market Challenges
    • Functional limitations pertaining to the use of neurotechnologies

Porter's Five Forces: A Strategic Tool for Navigating the Neuroscience Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuroscience Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuroscience Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuroscience Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuroscience Market

A detailed market share analysis in the Neuroscience Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuroscience Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuroscience Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuroscience Market

A strategic analysis of the Neuroscience Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroscience Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Brain Products GmbH, Compumedics Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilson, Inc., GL Sciences Inc., Hitachi, Ltd., Illumina, Inc., JASCO Corporation, Merck KGaA, Metrohm AG, Natus Medical Incorporated, Novasep Holding SAS, PerkinElmer Inc., Pfizer Inc., Promega Corporation, QIAGEN GmbH, Restek Corporation, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., Waters Corporation, and YMC Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroscience Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diagnostic Solution, Drug Therapy, and Non-drug Therapy. The Diagnostic Solution is further studied across Molecular and Non-molecular. The Molecular is further studied across Immunoassay, Instruments, Kits & Consumables, Liquid Chromatography, PCR, Sequencing, and Software. The Non-molecular is further studied across Brainstem auditory evoked potential, Electroencephalography, and Imaging. The Drug Therapy is further studied across Neurological disorders and Neuropsychiatric disorders. The Neurological disorders is further studied across Alzheimer's disease, Epilepsy, Huntington's disease, Multiple sclerosis, Parkinson's disease, and Vascular dementia. The Neuropsychiatric disorders is further studied across Anxiety, Attention deficit, Autism spectrum, Insomnia, Mood disorder, and Substance abuse. The Non-drug Therapy is further studied across Behavioral Therapy and Digital Health Services. The Behavioral Therapy is further studied across Animal-assisted, Home-based, Inpatient, and Outpatient.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of neurological disorders worldwide
      • 5.1.1.2. Rise in drug discovery and development for neurological conditions
      • 5.1.1.3. Increasing use of neuroscience to enhance brain health and cognitive functions
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with neuroscience research
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging use of neuroscience in the development of personalized medicine
      • 5.1.3.2. Favorable funding landscape for neuroscience research
    • 5.1.4. Challenges
      • 5.1.4.1. Functional limitations pertaining to the use of neurotechnologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuroscience Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostic Solution
    • 6.2.1. Molecular
      • 6.2.1.1. Immunoassay
      • 6.2.1.2. Instruments
      • 6.2.1.3. Kits & Consumables
      • 6.2.1.4. Liquid Chromatography
      • 6.2.1.5. PCR
      • 6.2.1.6. Sequencing
      • 6.2.1.7. Software
    • 6.2.2. Non-molecular
      • 6.2.2.1. Brainstem auditory evoked potential
      • 6.2.2.2. Electroencephalography
      • 6.2.2.3. Imaging
  • 6.3. Drug Therapy
    • 6.3.1. Neurological disorders
      • 6.3.1.1. Alzheimer's disease
      • 6.3.1.2. Epilepsy
      • 6.3.1.3. Huntington's disease
      • 6.3.1.4. Multiple sclerosis
      • 6.3.1.5. Parkinson's disease
      • 6.3.1.6. Vascular dementia
    • 6.3.2. Neuropsychiatric disorders
      • 6.3.2.1. Anxiety
      • 6.3.2.2. Attention deficit
      • 6.3.2.3. Autism spectrum
      • 6.3.2.4. Insomnia
      • 6.3.2.5. Mood disorder
      • 6.3.2.6. Substance abuse
  • 6.4. Non-drug Therapy
    • 6.4.1. Behavioral Therapy
      • 6.4.1.1. Animal-assisted
      • 6.4.1.2. Home-based
      • 6.4.1.3. Inpatient
      • 6.4.1.4. Outpatient
    • 6.4.2. Digital Health Services

7. Neuroscience Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Research & Academic Institutes

8. Americas Neuroscience Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Neuroscience Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Neuroscience Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Bayer AG
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Brain Products GmbH
  • 5. Compumedics Limited
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilson, Inc.
  • 9. GL Sciences Inc.
  • 10. Hitachi, Ltd.
  • 11. Illumina, Inc.
  • 12. JASCO Corporation
  • 13. Merck KGaA
  • 14. Metrohm AG
  • 15. Natus Medical Incorporated
  • 16. Novasep Holding SAS
  • 17. PerkinElmer Inc.
  • 18. Pfizer Inc.
  • 19. Promega Corporation
  • 20. QIAGEN GmbH
  • 21. Restek Corporation
  • 22. Shimadzu Corporation
  • 23. Siemens AG
  • 24. Thermo Fisher Scientific Inc.
  • 25. Waters Corporation
  • 26. YMC Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. NEUROSCIENCE MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROSCIENCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROSCIENCE MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY BRAINSTEM AUDITORY EVOKED POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY ATTENTION DEFICIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY AUTISM SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOOD DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY SUBSTANCE ABUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANIMAL-ASSISTED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOME-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIGITAL HEALTH SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. EGYPT NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. FINLAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. FINLAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. FRANCE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. FRANCE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 306. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. GERMANY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 308. GERMANY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 316. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. ISRAEL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 318. ISRAEL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 326. ITALY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 327. ITALY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. ITALY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 336. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 338. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 345. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 346. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 347. NIGERIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 348. NIGERIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 355. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 356. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 357. NORWAY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 358. NORWAY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 362. POLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 363. POLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 364. POLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2